APA (7th ed.) Citation

Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., . . . Lane, R. (2020). Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS. New England Journal of Medicine, 383(2), 109. https://doi.org/10.1056/NEJMoa2003715

Chicago Style (17th ed.) Citation

Miller, T., et al. "Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS." New England Journal of Medicine 383, no. 2 (2020): 109. https://doi.org/10.1056/NEJMoa2003715.

MLA (9th ed.) Citation

Miller, T., et al. "Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS." New England Journal of Medicine, vol. 383, no. 2, 2020, p. 109, https://doi.org/10.1056/NEJMoa2003715.